It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Assays to study cancer cell responses to pharmacologic or genetic perturbations are typically restricted to using simple phenotypic readouts such as proliferation rate. Information-rich assays, such as gene-expression profiling, have generally not permitted efficient profiling of a given perturbation across multiple cellular contexts. Here, we develop MIX-Seq, a method for multiplexed transcriptional profiling of post-perturbation responses across a mixture of samples with single-cell resolution, using SNP-based computational demultiplexing of single-cell RNA-sequencing data. We show that MIX-Seq can be used to profile responses to chemical or genetic perturbations across pools of 100 or more cancer cell lines. We combine it with Cell Hashing to further multiplex additional experimental conditions, such as post-treatment time points or drug doses. Analyzing the high-content readout of scRNA-seq reveals both shared and context-specific transcriptional response components that can identify drug mechanism of action and enable prediction of long-term cell viability from short-term transcriptional responses to treatment.
Large-scale screens of chemical and genetic vulnerabilities in cancer are typically limited to simple readouts of cell viability. Here, the authors develop a method for profiling post-perturbation transcriptional responses across large pools of cancer cell lines, enabling deep characterization of shared and context-specific responses.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34)
2 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Broad Institute of MIT and Harvard, Klarman Cell Observatory, Cambridge, USA (GRID:grid.66859.34)
3 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
4 Broad Institute of MIT and Harvard, Klarman Cell Observatory, Cambridge, USA (GRID:grid.66859.34); Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563)
5 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Pediatric Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581)
6 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Broad Institute of MIT and Harvard, Klarman Cell Observatory, Cambridge, USA (GRID:grid.66859.34); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581); Koch Institute of Integrative Cancer Research, Cambridge, USA (GRID:grid.413575.1); MIT, Department of Biology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
7 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)